MedTech Dive December 10, 2025
Foresight’s technology will be integrated into Natera’s Signatera platform and is expected to be launched for clinical use in 2026.
Dive Brief:
- Natera last week said it completed the acquisition of Foresight Diagnostics, expanding the company’s position in solid tumor molecular residual disease detection, particularly in lymphoma, a cancer of the lymphatic system.
- The all-stock transaction was valued at $275 million upfront, plus up to $175 million in revenue- and reimbursement-based milestone payments.
- Foresight’s PhasED-Seq technology will be integrated into Natera’s Signatera platform to further differentiate performance in solid tumors.
Dive Insight:
Foresight’s testing technology is a liquid biopsy approach that identifies small amounts of circulating tumor DNA left in the blood after treatment that can signal cancer...
Today's Sponsors
Today's Sponsor